Breast cancer Trials in Krasnodar, Russia
Conditions / Breast cancer / Krasnodar, Russia
Breast cancer has been the subject of sustained clinical investigation across multiple research sites.
15 total trials for this combination
Showing top 10 of 15 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04109066 | Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer | COMPLETED | PHASE3 |
| NCT03078036 | International Breast Cancer Biomarker,Standard of Care and Real World Outcomes Study | COMPLETED | — |
| NCT04109391 | Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03 | COMPLETED | PHASE3 |
| NCT00022672 | A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer | COMPLETED | PHASE3 |
| NCT01026142 | A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA) | COMPLETED | PHASE3 |
| NCT00388726 | E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer | COMPLETED | PHASE3 |
| NCT00091442 | A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer | COMPLETED | PHASE3 |
| NCT00099437 | Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy. | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT00338286 | A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy | COMPLETED | PHASE3 |
| NCT03556358 | Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer | COMPLETED | PHASE3 |